Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is a Healthcare company (Biotechnology) with a market capitalization of $3.1B. The Maz Rating grades it against the other companies in its sector.
Xeris Biopharma Holdings, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $16.80, Xeris Biopharma Holdings, Inc. trades at 8.3x sales and 61.9x book value, with an EV/EBITDA of 120.4. Over the last twelve months it generated about $371M of revenue and a net loss of $7M. It runs a gross margin of 84.4%, an operating margin of 12.7% and a net margin of -1.8%. It shows return on equity of -39.5%, return on invested capital of 15.9% and a free cash flow yield of 2.4%. On the balance sheet: a debt-to-equity ratio of 4.63 and a current ratio of 2.15. Over the past 52 weeks the share price ranged from $5.25 to $16.98, with a beta of 0.84.
Xeris Biopharma Holdings, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 10 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.